Cancer Panel

Cancer Methylation Panel

The silencing of tumor suppressor genes via DNA hypermethylation in promoter regions and the overexpression of transposable elements via global DNA hypomethylation are well documented phenomena associated with cancer. The discovery of cancer DNA methylation biomarkers is important for advancing clinical practice, such as the early diagnosis of cancer, the prognosis of disease progression/tumor recurrence, and the prediction of therapeutic response.

The 28 genes selected to be part of the Cancer Panel were chosen based on prior breast cancer studies EpigenDx conducted in collaboration with researchers at other institutes and universities. While many of the genes in the Cancer Panel were selected because of their association with breast cancer’s epigenetic profile, the highly skilled and well-trained technology experts at EpigenDx are available to assist you with your custom research needs, regardless of tissue type.

All methylation assays of the Cancer Panel were individually validated using DNA extracted from FFPE samples, but a subset of the panel was also validated using cell-free serum plasma DNA. While EpigenDx's Pyrosequencing service is ideal for the DNA methylation analysis of a few specific loci, EpigenDx also offers targeted Next-Generation Bisulfite Sequencing services for the simultaneous DNA methylation analysis of all genes on the Cancer Panel with quantitative CpG site specific results.

Cancer Panel Available as Kits or Services

Information: Cancer Methylation Panel
Platform: Targeted Next-Gen Bisulfite Sequencing
Pyrosequencing
Species: Human (Homo sapiens)
Stats: 300 CpG sites over 28 genes
Genes validated on FFPE samples: APC, BRCA1, CD44, CDKN1A, CDKN2A, CST6, DAPK1, EN1, ESR1, ESR2, GSTM2, GSTP1, HIST1H3C, HOXB4, LHX2, MAGEA1, PARP1, PDGFRA, PGR, PTGS2, RARB, RASGRF2, RASSF1, RUNX3, SGK1H, SOX17, TFF1, TMEFF2
Gene validated on serum plasma DNA: APC, BRCA1, CDKN2A, CST6, DAPK1, ESR2, GSTP1, HIST1H3C, HOXB4, RARB, RASGRF2, RUNX3, SOX17, TMEFF2
References: Exploring DNA methylation changes in promoter, intragenic, and intergenic regions as early and late events in breast cancer formation (Rauscher et al. 2015)
EpigenDx Cancer Panel Methylation Analysis Service
  • Send your samples to EpigenDx’s service laboratory.
  • Ability to accept all types of DNA (Serum, FFPE, etc.).
  • Versatility with Pyrosequencing and targeted Next-Gen Bisulfite Sequencing
  • EpigenDx provides a complete solution: DNA extraction, bisulfite modification, library preparation, sequencing, and data analysis.
  • Full result reports with an explanation of the data.
Cancer Panel Assay Kits
  • Primers compatible with IonTorrent™, all major NGS and Pyrosequencing technologies.
  • Primers good for 300 reactions.
  • Access to our knowledgeable and experienced customer service.